<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045539</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000256605</org_study_id>
    <secondary_id>NABTT-2109</secondary_id>
    <secondary_id>JHOC-NABTT-2109</secondary_id>
    <nct_id>NCT00045539</nct_id>
  </id_info>
  <brief_title>Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma</brief_title>
  <official_title>A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Brain Tumor Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different&#xD;
      ways to stop cancer cells from dividing so they stop growing or die. Combining more than one&#xD;
      drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with thiotepa in&#xD;
      treating patients who have newly-diagnosed primary CNS lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete radiographic response in patients with newly diagnosed primary&#xD;
           CNS lymphoma treated with methotrexate and thiotepa.&#xD;
&#xD;
        -  Determine the duration of progression-free survival and overall survival of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine whether tumor expression of BCL-6 is associated with response to this&#xD;
           chemotherapy regimen and survival of these patients.&#xD;
&#xD;
        -  Describe the relationship between initial response to steroids (if administered),&#xD;
           response to this chemotherapy regimen, and survival of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive thiotepa IV over 15 minutes on day 1. Patients also receive methotrexate IV&#xD;
      over 4 hours on days 1 (8 hours after thiotepa) and 14. Beginning 24 hours after the start of&#xD;
      methotrexate infusion, patients receive leucovorin calcium IV or orally every 6 hours until&#xD;
      rescue is achieved. Treatment repeats every 28 days for up to 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients achieving disappearance of enhancement&#xD;
      of disease on MRI receive an additional 28-day course followed by maintenance therapy&#xD;
      comprising thiotepa and methotrexate once a month for 11 courses.&#xD;
&#xD;
      Patients undergo neuro-ophthalmologic exams annually for 2 years.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-39 patients will be accrued for this study within 8-20&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete radiographic response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of tumor BCL-6 expression with response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship among initial response to steroids, response to chemotherapy, and survival</measure>
  </secondary_outcome>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary CNS lymphoma&#xD;
&#xD;
               -  Confirmed by 1 of the following:&#xD;
&#xD;
                    -  Brain biopsy or resection&#xD;
&#xD;
                    -  CSF cytology&#xD;
&#xD;
                         -  Positive cytology or immunohistochemical diagnosis of monoclonality and&#xD;
                            measurable intracranial tumor&#xD;
&#xD;
                    -  Vitreal biopsy&#xD;
&#xD;
          -  Measurable and contrast-enhancing disease on the postoperative, pretreatment MRI or CT&#xD;
             scan&#xD;
&#xD;
          -  No radiographic evidence of ascites or pleural effusions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 4 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Mini mental score of at least 15&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Able to achieve hydration&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ&#xD;
&#xD;
          -  No allergy to methotrexate&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No medical illness that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy or biologic therapy for this disease&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for this disease&#xD;
&#xD;
          -  No other concurrent chemotherapeutic agents&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy for this disease&#xD;
&#xD;
          -  Prior glucocorticoid therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for this disease&#xD;
&#xD;
          -  No prior cranial irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 1 week since prior salicylates, non-steroidal anti-inflammatory drugs,&#xD;
             probenecid, folic acid, or sulfonamide medications&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Batchelor, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

